Hepatitis B is a viral infection caused due to transmission of the virus through contact with the blood or other body fluids of an infected person. It is considered as a serious occupational hazard for healthcare professionals, which affects the liver, causing acute and chronic diseases. Hence, Chinese hamster ovary cell (CHO) hepatitis B vaccine is considered to be the safe and effective method to prevent the hepatitis B infection. The major factor that fuels the growth of the market are increase in prevalence of hepatitis B infection worldwide. For example, approximately 887,000 deaths due to hepatitis B infection were recorded in 2015 across the globe. However, inherent disadvantages of using recombinant Chinese hamster ovary cell (CHO) to design hepatitis B vaccines restrains the growth of the market. Conversely, increase in government focus to promote (CHO) hepatitis B vaccination for adults and extensive research carried out for the same are expected to offer lucrative opportunities for the market.
In 2019, the market size of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine.
This report studies the global market size of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Merck & Co., Inc.
GlaxoSmithKline Plc
Pfizer Inc.
Sanofi Pasteur
CSL Limited
Emergent Biosolutions
Serum Institute of India
Johnson & Johnson
Market Segment by Product Type
Pediatric Hepatitis B (CHO) Vaccine
Adult Hepatitis B (CHO) Vaccine
Market Segment by Application
Hospitals
Clinics
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)